A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Seagen Inc.
Pfizer
UMC Utrecht
A2 Biotherapeutics Inc.
Revolution Medicines, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Colorado, Denver
City of Hope Medical Center
University of Nebraska
Natera, Inc.
Novartis
Var2 Pharmaceuticals
City of Hope Medical Center
Massive Bio, Inc.
Chongqing Precision Biotech Co., Ltd
Washington University School of Medicine
A2 Biotherapeutics Inc.
Elicio Therapeutics
Guardant Health, Inc.
ModeX Therapeutics, An OPKO Health Company
Shanghai Cingularbio Co. Ltd
Columbia University
University of Arizona
Tempus AI
Instituto de Investigacion Sanitaria La Fe